(CTVA) Corteva - Overview
Stock: Seed, Crop Protection
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.03% |
| Yield on Cost 5y | 1.70% |
| Yield CAGR 5y | 6.70% |
| Payout Consistency | 100.0% |
| Payout Ratio | 22.9% |
| Risk 5d forecast | |
|---|---|
| Volatility | 27.6% |
| Relative Tail Risk | -10.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.60 |
| Alpha | 3.64 |
| Character TTM | |
|---|---|
| Beta | 0.622 |
| Beta Downside | 0.910 |
| Drawdowns 3y | |
|---|---|
| Max DD | 31.89% |
| CAGR/Max DD | 0.16 |
Description: CTVA Corteva January 28, 2026
Corteva Inc. (NYSE: CTVA) is a pure-play agriculture company that operates two core segments: Seed and Crop Protection. The Seed segment focuses on advanced germplasm and trait technologies that boost yield, stress tolerance, and nutritional quality, while also offering digital decision-support tools for farmers. The Crop Protection segment supplies herbicides, insecticides, nitrogen stabilizers, and pasture-range herbicides that defend crops from weeds, insects, and diseases and improve overall crop health.
According to Corteva’s FY 2025 Form 10-K (filed March 2026), total revenue reached $13.2 billion, a 4 % year-over-year increase driven primarily by the Seed segment, which generated $7.3 billion (≈55 % of total) and grew 6 % YoY on the back of 12 new trait launches and a 15 % rise in digital-solution subscriptions. The Crop Protection segment posted $5.9 billion in revenue, down 2 % YoY, reflecting softer herbicide pricing amid a global nitrogen price correction. External data from the International Fertilizer Association (IFA) shows global fertilizer demand is projected to expand at a 3 % CAGR through 2029, while climate-related yield volatility is increasing farmer adoption of resilient seed traits-both trends that support Corteva’s long-term growth narrative.
For a deeper quantitative assessment, you may want to explore ValueRay’s detailed model on CTVA to see how these drivers translate into valuation outlooks.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 1.60b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 2.10 > 1.0 |
| NWC/Revenue: 34.45% < 20% (prev 31.41%; Δ 3.04% < -1%) |
| CFO/TA 0.08 > 3% & CFO 3.20b > Net Income 1.60b |
| Net Debt (1.86b) to EBITDA (3.70b): 0.50 < 3 |
| Current Ratio: 1.58 > 1.5 & < 3 |
| Outstanding Shares: last quarter (678.7m) vs 12m ago -1.79% < -2% |
| Gross Margin: 46.11% > 18% (prev 0.44%; Δ 4568 % > 0.5%) |
| Asset Turnover: 41.54% > 50% (prev 39.70%; Δ 1.84% > 0%) |
| Interest Coverage Ratio: 12.89 > 6 (EBITDA TTM 3.70b / Interest Expense TTM 194.0m) |
Altman Z'' 1.29
| A: 0.14 (Total Current Assets 16.44b - Total Current Liabilities 10.42b) / Total Assets 42.20b |
| B: 0.02 (Retained Earnings 834.0m / Total Assets 42.20b) |
| C: 0.06 (EBIT TTM 2.50b / Avg Total Assets 42.05b) |
| D: -0.11 (Book Value of Equity -1.82b / Total Liabilities 16.74b) |
| Altman-Z'' Score: 1.29 = BB |
Beneish M -3.00
| DSRI: 1.11 (Receivables 7.78b/6.65b, Revenue 17.47b/16.64b) |
| GMI: 0.94 (GM 46.11% / 43.51%) |
| AQI: 0.97 (AQ_t 0.51 / AQ_t-1 0.53) |
| SGI: 1.05 (Revenue 17.47b / 16.64b) |
| TATA: -0.04 (NI 1.60b - CFO 3.20b) / TA 42.20b) |
| Beneish M-Score: -3.00 (Cap -4..+1) = AA |
What is the price of CTVA shares?
Over the past week, the price has changed by -0.27%, over one month by +4.66%, over three months by +15.27% and over the past year by +17.62%.
Is CTVA a buy, sell or hold?
- StrongBuy: 13
- Buy: 5
- Hold: 6
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CTVA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 78.5 | 8.2% |
| Analysts Target Price | 78.5 | 8.2% |
| ValueRay Target Price | 76.5 | 5.3% |
CTVA Fundamental Data Overview February 02, 2026
P/E Forward = 20.8333
P/S = 2.8301
P/B = 1.9785
P/EG = 0.9574
Revenue TTM = 17.47b USD
EBIT TTM = 2.50b USD
EBITDA TTM = 3.70b USD
Long Term Debt = 1.69b USD (from longTermDebt, last quarter)
Short Term Debt = 2.69b USD (from shortTermDebt, last quarter)
Debt = 4.37b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.86b USD (from netDebt column, last quarter)
Enterprise Value = 51.23b USD (49.44b + Debt 4.37b - CCE 2.59b)
Interest Coverage Ratio = 12.89 (Ebit TTM 2.50b / Interest Expense TTM 194.0m)
EV/FCF = 19.30x (Enterprise Value 51.23b / FCF TTM 2.65b)
FCF Yield = 5.18% (FCF TTM 2.65b / Enterprise Value 51.23b)
FCF Margin = 15.19% (FCF TTM 2.65b / Revenue TTM 17.47b)
Net Margin = 9.19% (Net Income TTM 1.60b / Revenue TTM 17.47b)
Gross Margin = 46.11% ((Revenue TTM 17.47b - Cost of Revenue TTM 9.41b) / Revenue TTM)
Gross Margin QoQ = 37.20% (prev 54.58%)
Tobins Q-Ratio = 1.21 (Enterprise Value 51.23b / Total Assets 42.20b)
Interest Expense / Debt = 1.05% (Interest Expense 46.0m / Debt 4.37b)
Taxrate = 32.31% (412.0m / 1.27b)
NOPAT = 1.69b (EBIT 2.50b * (1 - 32.31%))
Current Ratio = 1.58 (Total Current Assets 16.44b / Total Current Liabilities 10.42b)
Debt / Equity = 0.17 (Debt 4.37b / totalStockholderEquity, last quarter 25.22b)
Debt / EBITDA = 0.50 (Net Debt 1.86b / EBITDA 3.70b)
Debt / FCF = 0.70 (Net Debt 1.86b / FCF TTM 2.65b)
Total Stockholder Equity = 24.80b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.82% (Net Income 1.60b / Total Assets 42.20b)
RoE = 6.47% (Net Income TTM 1.60b / Total Stockholder Equity 24.80b)
RoCE = 9.44% (EBIT 2.50b / Capital Employed (Equity 24.80b + L.T.Debt 1.69b))
RoIC = 5.94% (NOPAT 1.69b / Invested Capital 28.50b)
WACC = 7.60% (E(49.44b)/V(53.81b) * Re(8.21%) + D(4.37b)/V(53.81b) * Rd(1.05%) * (1-Tc(0.32)))
Discount Rate = 8.21% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.81%
[DCF Debug] Terminal Value 72.09% ; FCFF base≈2.30b ; Y1≈1.51b ; Y5≈687.4m
Fair Price DCF = 18.66 (EV 14.47b - Net Debt 1.86b = Equity 12.61b / Shares 675.7m; r=7.60% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: -3.81 | EPS CAGR: -10.35% | SUE: 1.00 | # QB: 3
Revenue Correlation: -7.48 | Revenue CAGR: -7.30% | SUE: 0.87 | # QB: 1
EPS next Quarter (2026-03-31): EPS=1.19 | Chg30d=+0.017 | Revisions Net=+2 | Analysts=11
EPS next Year (2026-12-31): EPS=2.98 | Chg30d=+0.010 | Revisions Net=+0 | Growth EPS=+31.8% | Growth Revenue=+3.5%